|
Age, (per 1 year)
|
1.03
|
0.92–1.03
|
0.343
| | | |
|
Male sex
|
1.40
|
0.60–3.55
|
0.460
| | | |
|
Body mass index (per 1.0)
|
0.99
|
0.89–1.10
|
0.835
| | | |
|
Dyslipidemia
|
0.83
|
0.37–1.80
|
0.640
| | | |
|
Diabetes mellitus
|
1.24
|
0.51–2.77
|
0.618
| | | |
|
Current smoker
|
1.58
|
0.61–3.64
|
0.324
| | | |
|
Chronic kidney disease
|
1.52
|
0.65–4.16
|
0.351
| | | |
|
Hemodialysis
|
1.12
|
0.18–3.78
|
0.881
| | | |
|
Use of cilostazol
|
1.30
|
0.60–2.91
|
0.505
| | | |
|
Involvement of popliteal lesion
|
1.51
|
0.59–3.44
|
0.370
| | | |
|
Reference vessel diameter (per 1.0 mm)
|
0.96
|
0.40–2.43
|
0.925
| | | |
|
ISR length (per 10.0 mm)
|
1.04
|
0.98–1.10
|
0.172
|
1.04
|
0.97–1.10
|
0.251
|
|
Tosaka type III (occlusion)
|
2.10
|
0.85–4.73
|
0.102
|
1.39
|
0.55–3.23
|
0.463
|
|
PACSS grade 4 of native lesions
|
1.05
|
0.40–3.58
|
0.933
| | | |
|
Tibial runoff ≤1
|
1.65
|
0.72–3.61
|
0.224
| | | |
|
Use of PCB at ISR treatment
|
0.16
|
0.06–0.39
|
< 0.001
|
0.17
|
0.06–0.41
|
< 0.001
|
